Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jtos.2022.04.006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Progressive supranuclear palsy: an updated approach on diagnosis, treatment, risk factors and outlook in Mexico.
Gac Med Mex
January 2025
Laboratorio de Reprogramación Celular y Enfermedades Crónico-Degenerativas, Department of Physiology, Universidad Nacional Autónoma de México, Mexico City, Mexico.
Progressive supranuclear palsy (PSP) is a rare, atypical parkinsonism, characterized by the presence of intracerebral tau protein aggregates and determined by a wide spectrum of clinical features. The definitive diagnosis is postmortem and is identified through the presence of neuronal death, gliosis, and aggregates of the tau protein presented in the form of neurofibrillary tangles (MNF) with a globose appearance in regions such as the subthalamic nucleus, the substantia nigra, and the globus pallidus The findings in ancillary imaging studies, as well as fluids biomarkers, are not sufficient to support diagnosis of PSP but are used to rule out similar pathologies because there are still no specific or validated biomarkers for this disease. The current treatment of PSP is focused on reducing symptoms, although emerging therapies seek to counteract its pathophysiological mechanisms.
View Article and Find Full Text PDFOngoing post-COVID-19 symptoms and complaints among healthcare professionals.
J Infect Dev Ctries
December 2024
Family Medicine, Merkezefendi District Health Directorate, Denizli, Turkey.
Introduction: Post-COVID-19 syndrome refers to the occurrence of symptoms lasting more than 4 weeks in individuals who have recovered from COVID-19. This study aims to investigate the post-COVID-19 symptoms in healthcare professionals.
Methodology: This descriptive study included 166 healthcare professionals who had tested positive for COVID-19 via PCR at least four weeks prior and subsequently presented to the Family Medicine Clinic at Pamukkale University Training and Research Hospital.
Eating behaviours and associated lifestyle factors in a sample of Slovak adolescents.
Cent Eur J Public Health
December 2024
Institute of Hygiene, Faculty of Medicine, Comenius University in Bratislava, Bratislava, Slovak Republic.
Objectives: An unhealthy lifestyle, inappropriate eating habits, and inadequate physical activity are the most common risk factors affecting health and causing the premature onset of non-communicable diseases. The study aimed to evaluate lifestyle factors, eating habits, and daily regimens in a sample of Slovak adolescents.
Methods: The sample involves 524 students aged 15-22 years attending selected secondary schools from the model region of Bratislava, the capital of Slovakia.
Clinical and radiographic outcomes of extra-short implants (≤ 6 mm) in the posterior atrophic jaws: a retrospective cohort study.
Int J Implant Dent
January 2025
Department of Neurosciences, School of Dentistry, University of Padua, Padua, Italy.
Objective: This study aimed at investigating implant survival rate and marginal bone loss (MBL) around extra-short implants. The impact of the loading protocol and of the use of an intermediate abutment was also evaluated, to explore possible differences in terms of the outcome measures.
Materials And Methods: Patients with single or multiple mandibular or maxillary posterior edentulism rehabilitated using extra-short 5-6 mm long implants were included.
Efficacy and safety of preservative-free anti-glaucomatous eye drops (dorzolamide/timolol) in ocular hypertension and/or glaucoma.
Int Ophthalmol
January 2025
Chairman and Professor of Ophthalmology, Kasr Alainy Faculty of Medicine, Cairo University, Giza, Egypt.
Purpose: This study evaluated the efficacy, safety, and tolerability of a single-dose, preservative-free (PF) Dorzolamide/Timolol combination (Twinzol-SDU).
Methods: A 3-month single-arm, multicenter, prospective cohort study was conducted in Egypt between January 2021 and October 2022 on previously diagnosed and controlled patients with ocular hypertension and/or glaucoma. Efficacy was assessed using the change in intraocular pressure (IOP) after 6 and 12 weeks.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!